Abstracts tagged "Bone"

Abstract Number: 1019 • 2014 ACR/ARHP Annual Meeting
Targeting the Bone-Driven Metabolic OA Phenotype By a Novel Dual Amylin Calcitonin Receptor Agonist, KBP-056
Ditte Reker, Sara Toftegaard Hjuler, Kim Andreassen, Morten Asser Karsdal, Kim Henriksen and Anne C. Bay-Jensen, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) may be segregated into different disease phenotypes based on disease drivers; cartilage damage, joint inflammation or subchondral bone remodelling. Each phenotype may…
Abstract Number: 330 • 2014 ACR/ARHP Annual Meeting
Prolactin Reduces Bone Erosion in Adjuvant-Induced Arthritis
Maria G. Ledesma-Colunga, Norma Adan, Ana L. Reyes-Lopez, Fernando Lopez-Barrera, Gonzalo Martinez de la Escalera and Carmen Clapp, Institute of Neurobiology, National University of Mexico (UNAM), Queretaro, Mexico
Background/Purpose Bone erosion is an important feature of rheumatoid arthritis (RA) that frequently results in lifelong crippling. The receptor activator of NFkB ligand (RANKL)/osteoprotegerin (OPG)/RANK…
Abstract Number: 2792 • 2014 ACR/ARHP Annual Meeting
Methotrexate Prevents Inflammatory Osteolysis By Activation of the Adenosine a_2A Receptor (A2AR)
Aranzazu Mediero¹, Tuere Wilder² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, ³NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Prior studies demonstrate that adenosine, acting at A2AR, mediates the anti-inflammatory effects of methotrexate (MTX) in models of both acute and chronic inflammation. We…
Abstract Number: 2345 • 2014 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Prevents Deterioration in Bone Structure in a Mouse Model of Collagen-Induced Arthritis
Hiroto Yoshida, Mika Yagoto, Miho Suzuki, Keisuke Tanaka, Misato Hashizume and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a disease that typically induces secondary osteoporosis, which increases the risk of bone fractures and, consequently, mortality. Bone fracture is…
Abstract Number: 71 • 2013 ACR/ARHP Annual Meeting
Subchondral Bone Turnover and Osteophyte Formation Are Key Aspects In The Progression Of Osteoarthritis and May Be Assessed and Predicted By a-CTX
Morten Asser Karsdal¹, Janet L. Huebner², Virginia Byers Kraus², Diana J. Leeming¹, Edward Coleman², Gary E. McDaniel³, Kim M. Huffman³, Kim Henriksen¹ and Anne C. Bay-jensen¹, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ³Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritic disease. It is characterized by pathological changes in both bone and cartilage turnover as well…
Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting
Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Sebastian Kraus¹, Matthias Englbrecht¹, Juergen Rech², Roland Kocijan¹, Georg A. Schett¹ and Stephanie Finzel¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…
Abstract Number: 2729 • 2013 ACR/ARHP Annual Meeting
Identification Of Osteoarthritis Patients With Chronic Inflammation Driven Disease Progression
Anne Sofie Siebuhr¹, Kristian Kjaer Petersen², Lars Arendt-Nielsen³, Line Egsgaard², Thomas Navndrup Eskehave⁴, Ole Simonsen⁵, Claus Christiansen^4,6, Hans Christian Hoeck⁴, Morten Asser Karsdal⁷ and Anne C. Bay-Jensen⁸, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, ³Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Center for Sensory-Motor Interaction, Aalborg, Denmark, ⁴Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, ⁵Frederikshavn Hospital, Frederikshavn, Denmark, ⁶Nordic Bioscience, Herlev, Denmark, ⁷Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁸Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: In osteoarthritis (OA) it is evident that a subset of patients experiences chronic tissue inflammation and may benefit from anti-inflammatory treatment. The systemic inflammation…
Abstract Number: 1953 • 2013 ACR/ARHP Annual Meeting
The Progression of Cartilage Damage in Rheumatoid Arthritis: A Three Year Prospective 3T- Magnetic Resonance Imaging Study Examining Predictive Factors
Fiona M. McQueen¹, Alexandra McHaffie², Andrew Clarke², Arier Lee³, Quentin Reeves², Barbara Curteis¹ and Nicola Dalbeth⁴, ¹Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ²Radiology, Auckland District Health Board, Auckland, New Zealand, ³Biostatistics and Epidemiology, University of Auckland, Auckland, New Zealand, ⁴Auckland District Health Board, Auckland, New Zealand
Background/Purpose: Cartilage damage impacts on patient disability in RA. The aims of this MRI study were to investigate cartilage damage over 3 years and determine…
Abstract Number: 1857 • 2013 ACR/ARHP Annual Meeting
Identification Of SOX5 and SOX6 As Potent Regulators Of RANKL Expression Contributing To Bone Erosion In Rheumatoid Arthritis and Experimental Arthritis Model
Wenfeng Tan¹, Xiaoke Feng², Lingxiao Xu³, Ke Gan⁴, Fang Wang³, Miaojia Zhang⁵, Hui Wu⁶ and Betty P. Tsao⁷, ¹Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ²Rheumatology, the First Affiliated Hospital of Nanjing Medical University, China, Nanjing, China, ³Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, ⁴Rheumatology Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ⁵Department of Rheumatology, Jiangsu Provincial People's Hospital, Nanjing, China, ⁶Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁷Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA
Background/Purpose: We previously reported a RANKLpromoter SNP confers an elevated promoter activity after stimulation via binding to a SOX family transcription factor SOX5 and is…
Abstract Number: 1828 • 2013 ACR/ARHP Annual Meeting
In Vivo Cartilage-Specific Deletion Of Ephrin-B2 In Mice Results In Developmental Locomotory Defects Associated With Hip Bone Abnormality
Gladys Valverde-Franco¹, Bertrand Lussier², David Hum¹, Jiangping Wu³, Jean-Pierre Pelletier¹, Mohit Kapoor¹ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada, ³Laboratory of Immunology, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada
Background/Purpose: The ephrins and their related receptors comprise the largest subfamily of receptor protein-tyrosine kinases and have been implicated in mediating developmental events. We have…
Abstract Number: 1839 • 2013 ACR/ARHP Annual Meeting
Osteoclastogenesis Is Enhanced By Synovial Fluid Derived Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis
Akilan Krishnamurthy¹, Heidi Wähämaa¹, Vijay Joshua¹, Catia Cerqueira¹, Elena Ossipova², Nancy Vivar Pomiano³, Karin Lundberg², Vivianne Malmström⁴, Per-Johan Jakobsson⁵, Lars Klareskog⁵, Georg Schett⁶, Jimmy Ytterberg¹ and Anca I Catrina⁵, ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁶Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti citrullinated modified vimentin antibodies isolated from peripheral blood (PB) of RA patients induce osteoclasts (OC) formation from PB derived monocytes of healthy individuals.…
Abstract Number: 1481 • 2013 ACR/ARHP Annual Meeting
Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers
Hubert Marotte¹, Sara Djemouai², Béatrice Pallot-Prades², Hervé Locrelle³ and Thierry Thomas⁴, ¹LBTO INSERM U1059 University Jean Monnet, Saint-Etienne, France, ²University Hospital, Saint-Etienne, France, ³INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France, ⁴INSERM U1059 and University Hospital, Saint-Etienne, France
Background/Purpose: Rheumatoid arthritis is the most common joint inflammatory disease associated with an increased risk of bone fractures. The standard of therapeutic strategy is to…
Abstract Number: 1236 • 2013 ACR/ARHP Annual Meeting
Outcomes and Costs Of Sacral Insufficiency Fractures
Shahryar Hadavi¹, Sanam Kia¹, Christian Dejaco², Bhaskar Dasgupta² and Frances Borg³, ¹Rheumatology Department, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom
Background/Purpose: Sacral insufficiency fracture (SIF) is a poorly recognised cause of lower back pain in the elderly with significant potential morbidity. Diagnosis is often slow…
Abstract Number: 1131 • 2013 ACR/ARHP Annual Meeting
Peri-Articular Fractal Signature Analysis and Bone Mineral Density Measure Different Aspects Of Bone: Cross-Sectional Data From The Osteoarthritis Initiative
Jeffrey B. Driban¹, Felix Liu², Alina O'Brien³, Lori Lyn Price⁴, Grace H. Lo⁵, Michael C. Nevitt⁶, Charles Eaton⁷, Timothy E. McAlindon⁸ and John A. Lynch⁹, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²University of California at San Francisco, San Francisco, CA, ³Tufts Medical Center, Boston, MA, ⁴Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ⁵VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Medical Care Line and Research Care Line; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ⁶Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁷Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ⁸Division of Rheumatology, Tufts Medical Center, Boston, MA, ⁹Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA
Background/Purpose: Peri-articular fractal signature analysis (FSA) and bone mineral density (paBMD) are potentially cost-effective prognostic imaging markers for osteoarthritis (OA) progression. While we know that…
Abstract Number: 526 • 2013 ACR/ARHP Annual Meeting
Endochondral Bone Formation and Advanced Enthesitis Are Key Features Of Proteoglycan Induced Spondylitis Mouse Model Of Ankylosing Spondylitis
Gethin P Thomas¹, Hsu-Wen Tseng², Allison Pettit^3,4, Tibor T. Glant⁵, Allan McRae² and Matthew A. Brown⁶, ¹Translational Reserch Institute, University of Queensland Diamantina Institute, Woolloongabba, Australia, ²University of Queensland Diamantina Institute, Woolloongabba, Australia, ³Mater Research, Woolloongabba, Australia, ⁴University of Queensland Centre for Clinical Research, Herston, Australia, ⁵Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ⁶University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: Transition from an initial inflammatory phase to the disabling osteoproliferative phase in ankylosing spondylitis (AS) is very poorly understood. Elucidation of the mechanisms underlying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.